The aim of this study was to characterize
primary central nervous system lymphoma (PCNSL)
among Asian patients and to determine their outcomes
with different therapeutic modalities. Patients and
Methods: Between 1990 and 2005, 37 patients with
PCNSL were analyzed within 5 different treatment
groups: radiotherapy alone (arm A), combined chemoradiation
(arm B), chemotherapy alone with methotrexate
(MTX) ≥ 1 g/m2 (arm C), miscellaneous therapy (arm
D), and best supportive care (arm E). Results: The median
age at presentation was 59 years, and the majority
of patients were male (68%). All patients had aggressive
diffuse large B-cell lymphoma. The number of patients
in arms A to E were 6, 16, 3, 8 and 4, respectively.
The overall median survival was 7.4 months, 54.1
months, not reached, 8.9 months and 0.9 months, respectively.
Use of MTX 1-2.5 g/m2 per cycle and an
ECOG performance status of 0-2 were each associated
with improved survival on univariate analysis (p = 0.022
and p = 0.049, respectively). Compared to radiotherapy
alone, use of combined chemo-radiation was associated
with a trend towards improved overall median survival
(7.4 vs. 54.1 months, p = 0.058). Conclusion: The
clinical characteristics and treatment outcomes in our
Asian patients were comparable to those reported in
Western series. Use of MTX 1-2.5 g/m2 per cycle and
an ECOG performance status of 0-2 were associated
with improved survival.